IP Library › Granted Patent US 12,534,513
Granted Patent B2
US 12,534,513 · App. 17/934,785 · Granted Jan 27, 2026

Anti-SARS-CoV-2 antibodies derived from 2DD8

Inventors: Jacob Glanville (San Francisco, CA); Shahrad Daraeikia (San Francisco, CA); I-Chieh Wang (San Bruno, CA); Sindy Andrea Liao Chan (San Jose, CA); Jean-Philippe Bürckert (Belmont, CA); Sawsan Youssef (Menlo Park, CA)
Assignee: Centivax, Inc.
C07K16/1018C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,534,513
App. No.
17/934,785
Granted
Jan 27, 2026
Kind
B2
Abstract

This disclosure provides antibodies and antigen-binding fragments that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments herein can be used to diagnose a SARS-CoV-2 infection.

Claims (6)

1 . An antibody or an antigen-binding fragment that selectively binds to a severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), that comprises:

(i) a variable heavy chain (VH) complementarity determining region 1 (CDR1) having an amino acid sequence of SEQ ID NO: 55, a VH CDR2 having an amino acid sequence of SEQ ID NO: 90, a VH CDR3 having an amino acid sequence of SEQ ID NO: 28, a variable light chain (VL) CDR1 having an amino acid sequence of SEQ ID NO: 9, a VL CDR2 having an amino acid sequence of SEQ ID NO: 104, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 117;

(ii) a VH CDR1 having an amino acid sequence of SEQ ID NO: 44, a VH CDR2 having an amino acid sequence of SEQ ID NO: 80, a VH CDR3 having an amino acid sequence of SEQ ID NO: 17, a VL CDR1 having an amino acid sequence of SEQ ID NO: 9, a VL CDR2 having an amino acid sequence of SEQ ID NO: 104, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 109;

(iii) a VH CDR1 having an amino acid sequence of SEQ ID NO: 61, a VH CDR2 having an amino acid sequence of SEQ ID NO: 97, a VH CDR3 having an amino acid sequence of SEQ ID NO: 24, a VL CDR1 having an amino acid sequence of SEQ ID NO: 9, a VL CDR2 having an amino acid sequence of SEQ ID NO: 104, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 114;

(iv) a VH CDR1 having an amino acid sequence of SEQ ID NO: 43, a VH CDR2 having an amino acid sequence of SEQ ID NO: 79, a VH CDR3 having an amino acid sequence of SEQ ID NO: 16, a VL CDR1 having an amino acid sequence of SEQ ID NO: 9, a VL CDR2 having an amino acid sequence of SEQ ID NO: 105, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 108; or

(v) a VH CDR1 having an amino acid sequence of SEQ ID NO: 61, a VH CDR2 having an amino acid sequence of SEQ ID NO: 89, a VH CDR3 having an amino acid sequence of SEQ ID NO: 24, a VL CDR1 having an amino acid sequence of SEQ ID NO: 9, a VL CDR2 having an amino acid sequence of SEQ ID NO: 104, and a VL CDR3 having an amino acid sequence of SEO ID NO: 115.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2025
From: GLANVILLE, JACOB; DARAEIKIA, SHAHRAD; WANG, I-CHIEH; LIAO CHAN, SINDY ANDREA; BÜRCKERT, JEAN-PHILIPPE; YOUSSEF, SAWSAN
To: CENTIVAX, INC.
Reel/Frame 071453/0610 →
Continuity (5)
Continuation PCTUS2021023449 · Mar 22, 2021
Provisional Application 63014946 · Apr 24, 2020
Provisional Application 62993630 · Mar 23, 2020
Provisional Application 63074043 · Sep 3, 2020
Related Publication 20230272051A1 · Aug 31, 2023
References Cited (151)
US 4676980A · Segal et al. · 1987 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5750373A · Garrard et al. · 1998 [cited by applicant]
US 10822379B1 · Dimitrov et al. · 2020 [cited by applicant]
US 11021531B1 · Glanville et al. · 2021 [cited by applicant]
US 11021532B1 · Glanville et al. · 2021 [cited by applicant]
US 11028150B1 · Glanville et al. · 2021 [cited by applicant]
US 11028167B1 · Glanville et al. · 2021 [cited by applicant]
US 11034762B1 · Glanville et al. · 2021 [cited by applicant]
US 11053304B1 · Glanville et al. · 2021 [cited by applicant]
US 20050037421A1 · Honda et al. · 2005 [cited by applicant]
US 20240270825A1 · Glanville et al. · 2024 [cited by applicant]
CN 111303279A · 2020 [cited by applicant]
CN 111333722A · 2020 [cited by applicant]
CN 111592594A · 2020 [cited by applicant]
WO WO8704462A1 · 1987 [cited by applicant]
WO WO9404690A1 · 1994 [cited by applicant]
WO WO9958572A1 · 1999 [cited by applicant]
WO WO2004058184A2 · 2004 [cited by applicant]
WO WO2005054469A1 · 2005 [cited by applicant]
WO WO2021045836A1 · 2021 [cited by applicant]
WO WO2021194886A1 · 2021 [cited by applicant]
WO WO2021194891A1 · 2021 [cited by applicant]
WO WO2021194896A1 · 2021 [cited by applicant]
WO WO2021194951A1 · 2021 [cited by applicant]
WO WO2021194965A1 · 2021 [cited by applicant]
WO WO2021194985A1 · 2021 [cited by applicant]
Aiola, C. @Chrisaiola. Dr. Jake Glanville and I discuss what we can expect in the coming weeks, why Covid-19 is much more dangerous than seasonal influenza, and his team's continuing effort to bio-engineer antibodies. @… [cited by applicant]
Aiola, Chris. Dr. Jake Glanville—Mar. 15, 2020. YouTube video (transcript). Transcribed Sep. 16, 2020 from URL: https://www.youtube.com/watch?v=bEjk-bLVW_8&feature=youtu.be. Mar. 16, 2020. 6 pages. [cited by applicant]
Altschul, S., et al., NCBI NLM NIH Bethesda, MD. 20894, pp. 403-410 (1990). [cited by applicant]
Altschul, Stephen F. et al. Basic Local Alignment Search Tool. Journal of Molecular Biology 215(3):403-410 (1990). [cited by applicant]
Altschul, Stephen F. et al. Gapped Blast and PSI-Blast: a new Generation of Protein Database Search Programs. Nucleic Acids Research 25(17):3389-3402 (1997). [cited by applicant]
Ausubel, Frederick et al. Current Protocols in Molecular Biology. Greene Publishing Associates and Wiley-Interscience (1987). [cited by applicant]
Ausubel, Frederick M. et al. Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology. Wiley (1999). [cited by applicant]
Barbas, Carlos F. et al. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A 91(9):3809-3813 (1994… [cited by applicant]
Beeman. Netflix's ‘Pandemic’ Doctor Says He May Have Found a Treatment for Coronavirus. Heavy (Apr. 10, 2020). Retrieved Sep. 18, 2020 at URL: https://heavy.com/news/2020/04/jacob-glanville-netflix-pandemic-doctor-coron… [cited by applicant]
Biocca, Silvia. et al. Expression and Targeting of Intracellular Antibodies in Mammalian Cells. The EMBO Journal 9(1):101-108 (1990). [cited by applicant]
Bird, Robert E. et al. Single-Chain Antigen-Binding Proteins. Science 242(4877):423-426 (1988). [cited by applicant]
Boerner, Paula. et al. Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-primed Human Splenocytes. Journal of Immunology 147(1):86-95 (1991). [cited by applicant]
Brouwer et al.: Potent neutralizing antibodies from Covid-19patients define multiple targets of vulnerability. Science. 369:643-650 (2020). [cited by applicant]
Carrillo, Humberto, and David Lipman. The Multiple Sequence Alignment Problem in Biology. SIAM Journal on Applied Mathematics 48(5):1073-1082 (1988). [cited by applicant]
Celis, Julio E. Cell Biology: A Laboratory Handbook, 2nd Edition. Academic Press (1998). [cited by applicant]
Centivax Antibodies Neutralize the Pandemic Coronavirus, Independently Confirmed by Three Research Laboratories (USAMRIID, Stanford, and UTMB/GNL). Business Wire (May 18, 2020). Retrieved Jul. 27, 2020 at URL: https://w… [cited by applicant]
Chen, Junsen. et al. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against Covid-19. Virologica Sinica 35(6):713-724 (2020). [cited by applicant]
CNBC's Closing Bell. @CNBCClosingBell. .@distributedbio is developing a Covid-19 treatment using antibodies produced during the 2002 SARS outbreak. Founder & CEO Dr. @CurleyJungleJake joined US to talk more about the ti… [cited by applicant]
Cohen, J. @Sciencecohen. In parallel with vaccine race, 50+ groups are making a boatload of SARS-CoV-2 monoclonal antibodies from recovered patients like Dr. X, mice, SARS-CoV, and computer programs. Yes, access, produc… [cited by applicant]
Cohen. The race is on for antibodies that stop the new coronavirus. Science (May 5, 2020). Retrieved Aug. 8, 2020 at URL: https://www.sciencemag.org/news/2020/05/race-antibodies-stop-new-coronavirus/ . 10 pages. [cited by applicant]
Colby, David W. et al. Potent Inhibition of Huntingtin Aggregation and Cytotoxicity by a Disulfide Bond-free Single-domain Intracellular Antibody. Proceedings of the National Academy of Sciences of the United States of … [cited by applicant]
Cole, S.P.C. et al. The EBV-Hybridoma Technique and its Application to Human Lung Cancer. Monoclonal Antibodies and Cancer Therapy 27:77-96 (1985). [cited by applicant]
Coligan, John E. Current Protocols in Immunology. John Wiley and Sons (1991). [cited by applicant]
Coronavirus is ‘much worse’ than influenza: Doctor. Fox Business News. Video (transcript). Transcribed Sep. 16, 2020 from URL: https://video.foxbusiness.com/v/6142665270001/#sp=show-clips. Mar. 18, 2020. 3 pages. [cited by applicant]
Devereux, John. et al. A Comprehensive Set of Sequence Analysis Programs for the VAX. Nucleic Acids Research 12(1):387-395 (1984). [cited by applicant]
Distributed Bio CEO on developing therapeutic antibody treatment against coronavirus. CNBC Squawk on the Street video (transcript). Transcribed Sep. 16, 2020 from URL: https://www.cnbc.com/video/2020/03/23/distributed-b… [cited by applicant]
Distributed Bio. @Distributedbio. An update on our monoclonal antibodies being engineered against #COVID19 from @CurlyJungleJake on @SquawkCNBC this morning. (Tweet). Twitter (Mar. 23, 2020). Retrieved Jul. 30, 2020 fro… [cited by applicant]
Distributed Bio. @Distributedbio. Hear more about our progress on engineering our #monoclonal #antibodies to neutralize #COVID19 from @CurlyJungleJake on @TheStoryFNC with @marthamaccallum (Tweet). Twitter (Mar. 19, 202… [cited by applicant]
Distributed Bio. @Distributedbio. It was a blast working with @chrisaiola and @ZPZProduction re #influenza for #Pandemic on #Netflix—hear more about #coronavirus here. (Tweet). Twitter (Mar. 3, 2020). Retrieved Jul. 30,… [cited by applicant]
Dr. Glanville: 3 to 4 weeks before completing engineering on drug that neutralizes coronavirus. Fox News. Video (transcript). Transcribed Sep. 16, 2020 from URL: https://video.foxnews.com/v/6142979870001#sp=show-clips. … [cited by applicant]
Fighting the Pandemic: Potential Covid-19 Treatment. CNBC Closing Bell video (transcript). Transcribed Sep. 16, 2020 from URL: https://twitter.com/CNBCClosingBell/status/1252681883772694533?s=20. Apr. 21, 2020. 2 pages. [cited by applicant]
Fredericks, Zoey L. et al. Identification of Potent Human Anti-IL-1RI Antagonist Antibodies. Protein Engineering, Design & Selection 17(1):95-106 (2004). [cited by applicant]
Freshney, R Ian. Culture of Animal Cells: A Manual of Basic Technique, 2nd Edition. Alan R. Liss (1987). [cited by applicant]
Gait, M J. Oligonucleotide Synthesis: A Practical Approach. IRL Press Limited (1984). [cited by applicant]
Gennaro, Alfonso R. Remington's Pharmaceutical Sciences, 18th Edition. Mack Publishing Company (1990). [cited by applicant]
Gennaro, Alfonso R. Remington: The Science and Practice of Pharmacy, 20th Edition. Lippincott Williams & Wilkins (2000). [cited by applicant]
Getz, Elise Burmeister et al. A Comparison Between the Sulfhydryl Reductants Tris(2-carboxyethyl)phosphine and Dithiothreitol for Use in Protein Biochemistry. Analytical Biochemistry 273(1):73-80 (1999). [cited by applicant]
Glanville et al. Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation. PNAS 108(50):20066-20071 (Dec. 13, 2011). DOI: https://doi.org/10.1073/pnas.1107498108. [cited by applicant]
Glanville et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. PNAS 106(48):20216-20221 (Dec. 1, 2009). URL: https://doi.org/10.1073/p… [cited by applicant]
Glanville et al. Deep sequencing in library selection projects: what insight does it bring? Current Opinion in Structural Biology 33:146-160 (Aug. 2015). DOI: https://doi.org/10.1016/j.sbi.2015.09.001. [cited by applicant]
Glanville et al. Identifying specificity groups in the T cell receptor repertoire. Nature 547:94-98 (Jul. 6, 2017). [cited by applicant]
Glanville, J. @CurlyJungleJake. Interview on @FoxBusiness where we discuss our #antibody therapeutics program for the #coronavirus. (Tweet). Twitter (Mar. 18, 2020). Retrieved Jul. 30, 2020 from https://twitter.com/Curl… [cited by applicant]
Gribskov, Michael, and John Devereux. Sequence Analysis Primer. M Stockton Press, New York (1991). [cited by applicant]
Griffin, Hugh G. et al. Part I: Computer Analysis of Sequence Data. Methods in Molecular Biology, Humana Press Inc 25:1-8 (1994). [cited by applicant]
Harlow, Ed. et al. Chapter 11: Epitope Mapping. In Using Antibodies, a Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1-5 (1999). [cited by applicant]
Hawkins, Robert E. et al. Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Matruation. Journal of Molecular Biology 226(3):889-896 (1992). [cited by applicant]
Heng, Boon Chin, and Tong, Cao. Making Cell-Permeable Antibodies (Transbody) Through Fusion of Protein Transduction Domains (PTD) With Single Chain Variable Fragment (scFv) Antibodies: Potential Advantages Over Antibodi… [cited by applicant]
Holliger, Philipp. et al. “Diabodies”: Small Bivalent and Bispecific Antibody Fragments. Proceedings of the National Academy of Sciences of the United States of America 90(14):6444-6448 (1993). [cited by applicant]
Hoogenboom, Hennie R, and Greg Winter. By-Passing Immunisation: Human Antibodies From Synthetic Repertoires of Germline VH Gene Segments Rearranged In Vitro. Journal of Molecular Biology 227(2):381-388 (1992). [cited by applicant]
Huston, James S. et al. Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-chain Fv Analogue Produced in [cited by applicant]
Hwang, William C. et al. Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80R. Journal of Biological Chemistry 281(45):34610-34615 (2006). [cited by applicant]
Jackson, Jeffrey R. et al. In vitro antibody maturation. Improvement of a high affinity, neutralizing antibody against IL-1 beta. J Immunol. 154(7):3310-3319 (1995). [cited by applicant]
Janeway, Charles Alderson. et al. Chapter 3: Structure of the antibody molecule and Immunoglobulin genes, Immunobiology: The Immune System in Health and Disease, 3rd Edition. Current Biology limited, Garland Publishing … [cited by applicant]
Köhler, G, and C. Milstein. Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity. Nature 256(5517):495-497 (1975). [cited by applicant]
Lesk, Arthur M. Computational Molecular Biology: Sources and Methods for Sequence Analysis. Oxford University Press, New York (1988). [cited by applicant]
Liew. The Flu, Snake Bites, and the Covid-19 Virus: Jacob Glanville from Netflix's ‘Pandemic.’ Harnham (Jan. 30, 2020). Retrieved Sep. 5, 2020 at URL: https://www.harnham.com/us/post/2020-1/a-discussion-with-jacob-glanv… [cited by applicant]
MacCallum, Robert M. et al. Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography. Journal of Molecular Biology 262(5):732-745 (1996). [cited by applicant]
Marks, James D. et al. By-Passing Immunization. Human Antibodies From V-Gene Libraries Displayed on Phage. Journal of Molecular Biology 222(3):581-597 (1991). [cited by applicant]
Marks, James. et al. By-passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling. Bio/Technology 10(7):779-783 (1992). [cited by applicant]
Mather, Jennie P, and Penelope E. Roberts. Introduction to Cell and Tissue Culture: Theory and Technique. Plenum Press (1998). [cited by applicant]
McCafferty, J. et al. Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains. Nature 348(6301):552-554 (1990). [cited by applicant]
Mhashilkar, Abner M. et al. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. The EMBO Journal 14(7):1542-1551 (1995). [cited by applicant]
Millstein, C, and A. C. Cuello. Hybrid Hybridomas and Their Use in Immunohistochemistry. Nature 305(5934):537-539 (1983). [cited by applicant]
Mullis, Kary B. et al. The Polymerase Chain Reaction. Springer Science+Business Media (1994). [cited by applicant]
Muyldermans, Serge. et al. Sequence and Structure of Vh Domain From Naturally Occurring Camel Heavy Chain Immunoglobulins Lacking Light Chains. Protein Engineering 7(9):1129-1135 (1994). [cited by applicant]
Nie, Jianhui. et al. Establishment and Validation of a Pseudovirus Neutralization Assay for SARS-CoV-2. Emerging Microbes & Infections 9(1):680-686 (2020). [cited by applicant]
Notice of Allowance dated Feb. 12, 2021 for U.S. Appl. No. 15/931,648. [cited by applicant]
Notice of Allowance dated Feb. 12, 21 for U.S. Appl. No. 15/931,642. [cited by applicant]
Notice of Allowance dated Feb. 16, 21 for U.S. Appl. No. 15/931,652. [cited by applicant]
Notice of Allowance dated Feb. 18, 2021 for U.S. Appl. No. 15/931,643. [cited by applicant]
Notice of Allowance dated Feb. 18, 2021 for U.S. Appl. No. 15/931,649. [cited by applicant]
Notice of Allowance dated Feb. 18, 2021 for U.S. Appl. No. 15/931,654. [cited by applicant]
Office action dated Oct. 21, 2020 for U.S. Appl. No. 15/931,642. [cited by applicant]
Office action dated Oct. 21, 2020 for U.S. Appl. No. 15/931,648. [cited by applicant]
Office action dated Oct. 21, 2020 for U.S. Appl. No. 15/931,652. [cited by applicant]
Office action dated Oct. 29, 2020 for U.S. Appl. No. 15/931,643. [cited by applicant]
Office action dated Oct. 29, 2020 for U.S. Appl. No. 15/931,649. [cited by applicant]
Office action dated Oct. 29, 2020 for U.S. Appl. No. 15/931,654. [cited by applicant]
Olafsen, Tove. et al. Characterization of Engineered Anti-p185HER-2 (scFv-CH3)2 Antibody Fragments (Minibodies) for Tumor Targeting. Protein Engineering, Design and Selection 17(4):315-323 (2004). [cited by applicant]
Osbourn, Jane K et al. Directed Selection of MIP-1α Neutralizing CCR5 Antibodies From a Phage Display Human Antibody Library. Nature Biotechnology vol. 16,8: pp. 778-781 (1998). [cited by applicant]
Pak, John E., et al. Structural Insights into Immune Recognition of the Severe Acute Respiratory Syndrome Coronavirus S Protein Receptor Binding Domain. Journal of Molecular Biology 388(4):815-823 (2009). [cited by applicant]
PCT/US2021/023237 International Search Report and Written Opinion dated Jun. 16, 2021. [cited by applicant]
PCT/US2021/023263 International Search Report and Written Opinion dated Jun. 16, 2021. [cited by applicant]
PCT/US2021/023296 International Search Report and Written Opinion dated Jun. 17, 2021. [cited by applicant]
PCT/US2021/023449 International Search Report and Written Opinion dated Jun. 17, 2021. [cited by applicant]
PCT/US2021/023477 International Search Report and Written Opinion dated Jun. 18, 2021. [cited by applicant]
PCT/US2021/023515 International Search Report and Written Opinion dated Jun. 16, 2021. [cited by applicant]
Pinto, Dora. et al. Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature 583(7815):290-295 (2020). [cited by applicant]
Pluckthun, A. Chapter 11: Antibodies From [cited by applicant]
Poljak, Roberto J. Production and Structure of Diabodies. Structure 2(12):1121-1123 (1994). [cited by applicant]
Powers, David B. et al. Expression of Single-chain Fv-fc Fusions in [cited by applicant]
Prabakaran, Ponraj. et al. Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-Binding Domain Complexed With Neutralizing Antibody. The Journal of Biological Chemistry 281(23):15829-15836 (2006). [cited by applicant]
Reiter, Yoram. et al. Engineering Antibody Fv Fragments for Cancer Detection and Therapy: Bisulfide-stabilized Fv Fragments. Nature Biotechnology 14(10):1239-1245 (1996). [cited by applicant]
Rudikoff, Stuart. et al. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences of the United States of America 79(6):1979-1983 (1982). [cited by applicant]
Sambrook, Joseph. et al. Molecular Cloning: A Laboratory Manual, 2nd Edition. Cold Spring Harbor Laboratory Press (1989). [cited by applicant]
Schier, Robert. et al. Identification of functional and structural amino-acid residues by parsimonious mutagenesis. Gene 169(2):147-155 (1996). [cited by applicant]
Scientists begin their study of covid-19, looking for antibody. Radio New Zealand (RNZ) broadcast (transcript). Transcribed Sep. 16, 2020 from URL: https://www.rnz.co.nz/national/programmes/first-up/audio/2018736849/sci… [cited by applicant]
Sheets, Michael D. et al. Efficient Construction of a Large Nonimmune Phage Antibody Library: The Production of High-affinity Human Single-chain Antibodies to Protein Antigens. Proceedings of the National Academy of Sci… [cited by applicant]
Shepherd, Philip, and Christopher J. Dean. Monoclonal Antibodies: A Practical Approach. Oxford University Press (2000). [cited by applicant]
Silverman, Joshua. et al. Corrigendum: Multivalent Avimer Proteins Evolved by Exon Shuffling of a Family of Human Receptor Domains. Nature Biotechnology 24(2):220 (2006). [cited by applicant]
Silverman, Joshua. et al. Multivalent Avimer Proteins Evolved by Exon Shuffling of a Family of Human Receptor Domains. Nature Biotechnology 23(12):1556-1561 (2005). [cited by applicant]
Smith, Douglas W. Genome Informatics: Biocomputing—Informatics and Genome Projects. Academic Press, New York (1993). [cited by applicant]
Suresh, M. R. et al. Bispecific Monoclonal Antibodies From Hybrid Hybridomas. Methods in Enzymology 121:210-228 (1986). [cited by applicant]
Tian, Xiaolong. et al. Potent Binding of 2019 Novel Coronavirus Spike Protein by a SARS Coronavirus-Specific Human Monoclonal Antibody. Emerging Microbes & Infections 9(1):382-385 (2020). [cited by applicant]
Vaughan, Tristan. et al. Human Antibodies With Sub-Nanomolar Affinities Isolated From a Large Non-immunized Phage Display Library. Nature Biotechnology 14(3):309-314 (1996). [cited by applicant]
Villasanta. Coronavirus Vaccine: Netflix Doctor Says He Found ‘Very Potent’ Drug to Treat Covid-19. International Business Times (Apr. 1, 2020). Retrieved Sep. 18, 2020 at URL: https://www.ibtimes.com/coronavirus-vaccin… [cited by applicant]
Von Heijne, Gunnar. Sequence Analysis in Molecular Biology, 1st Edition. Academic Press (1987). [cited by applicant]
Walls et al. Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. Cell. Feb. 21, 2019; 176(5): 1026-1039.e15. Published online Jan. 3, 20191. doi: 10.1016/j.cell.2018.12.028. [cited by applicant]
Wang, Chunyan. et al. A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection. Nature Communications 11(1):2251, 1-6 (2020). [cited by applicant]
Weir, D M. et al. Handbook of Experimental Immunology. Blackwell Scientific Publications (1986). [cited by applicant]
Wheeler, Yurong Yang. et al. Intrabody-Based Strategies for Inhibition of Vascular Endothelial Growth Factor Receptor-2: Effects on Apoptosis, Cell Growth, and Angiogenesis. The FASEB Journal 17(12):1733-1735 (2003). [cited by applicant]
Woods. Doctor in Netflix's ‘Pandemic’ says he discovered potential coronavirus cure. New York Post (Apr. 1, 2020). Retrieved Sep. 18, 2020 at URL: https://nypost.com/2020/04/01/doctor-in-netflix-doc-says-he-discovered-p… [cited by applicant]
Yelton, Dale E. et al. Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis. The Journal of Immunology 155(4): 1994-2004 (1995). [cited by applicant]
Yuan, et al. A Highly Conserved Cryptic Epitope in the Receptor Binding Domains of SARS-CoV-2 and SARS-CoV. Science. vol. 368, Issue 6491 (2020): 630-633. [cited by applicant]
Zanetti, Maurizio, and J, Donald Capra. The Antibodies, vol. I. Harwood Academic Publishers (1995). [cited by applicant]
Zhai et al. Synthetic antibodies designed on natural sequence landscapes. J Mol Biol 412(1):55-71 (Sep. 9, 2011). Epub Jul. 23, 2011. doi: 10.1016/j.jmb.2011.07.018. [cited by applicant]
Jahanshahlu, Leila, et al. Monoclonal antibody as a potential anti-COVID-19. Biomedicine & Pharmacotherapy 129(110337) (2020), 4 pages. [cited by applicant]